Page 345 - Programme book for The International Liver Congress 2015, EASL ILC 2015

P1323 A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, ePOSTERS
PHARMACOKINETICS AND PHARMACODYNAMICS OF
YI P1324 REPEAT DOSES OF GSK2330672 ADMINISTRATION IN
YI P1325 SUBJECTS WITH PRIMARY BILIARY CIRRHOSIS AND
YI P1326 SYMPTOMS OF PRURITUS
YI P1327 Vinod S. Hegade*, Stuart Kendrick, Robert Dobbins, Jim Storey,
YI P1328 Sam R. Miller, George F. Mells, Graeme Alexander, Gideon Hirschfield,
David E. Jones, The United Kingdom

THE HOME STUDY (HOME MONITORING IN
ENCEPHALOPATHY): RATIONALE AND STUDY DESIGN
James G. Orr*, Mark Hudson, Calum J. McNeil, David E. Jones,
The United Kingdom

EFFICACY AND SAFETY OF COMBINED SEQUENTIAL
TREATMENT WITH RFA AND SORAFENIB IN PATIENTS
WITH HCC IN INTERMEDIATE STAGE INELIGIBLE FOR
TACE: A PROSPECTIVE RANDOMIZED OPEN STUDY
Giorgio de Stefano*, Valentina Iodice, Giuseppe Signoriello,
Umberto Scognamiglio, Nunzia Farella, Italy

PASIREOTIDE IN ADDITION TO ASPIRATION
SCLEROTHERAPY TO IMPROVE TREATMENT OF LARGE
SYMPTOMATIC HEPATIC CYSTS: A RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Titus F. Wijnands*, Tom J. Gevers, Leo J. Schultze Kool, Joost P. Drenth,
The Netherlands

ATTIRE: ALBUMIN TO PREVENT INFECTION IN CHRONIC
LIVER FAILURE
Louise China*, James Fullerton, Marc George, Simon Skene,
Zainib Shabir, Derek Gilroy, Alastair O’Brien, The United Kingdom

RITPBC: B-CELL DEPLETING THERAPY (RITUXIMAB)
AS A TREATMENT FOR FATIGUE IN PRIMARY BILIARY
CIRRHOSIS: STUDY PROTOCOL FOR A RANDOMISED
CONTROLLED TRIAL
Laura Jopson*, Julia L. Newton, Denise Howel, Jeremy Palmer,
John Isaacs, Jessica Qian, Jennifer Wilkinson, Andrew Blamire,
Achilleas Floudas, David E. Jones, The United Kingdom

Vienna, Austria • April 22–26, 2015 345